Toivo Maimets

Dr. Toivo Maimets

orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2008 in Oncogene
Verified
Journal Article
Closed access
TMToivo Maimets
Toivo Maimets
INI Neganova
I Neganova
LAL Armstrong
L Armstrong
MLM Lako
M Lako

1 January 2008 in Molecular Therapy
Verified
Journal Article
Open access
HJHenrik J Johansson
Henrik J Johansson
SESamir El-Andaloussi
Samir El-Andaloussi
THTina Holm
Tina Holm
MMMaarja Mäe
Maarja Mäe
JJJaak Jänes
Jaak Jänes
ULUlo Langel
Ulo Langel
The tumor suppressor p14ARF is widely deregulated in many types of cancers and is believed to function as a failsafe mechanism, inhibiting proliferation and inducing apoptosis as cellular response to a high oncogene load. We have found that a 22-amino-acid-long peptide derived from the N-terminal part of p14ARF, denoted ARF(1–22), which has previously been shown to mimic the function of p14ARF, has cell-penetrating properties. This peptide is internalized to the same extent as the cell-penetrating peptide (CPP) TP10 and dose-dependently decreases proliferation in MCF-7 and MDA MB 231 cells. Uptake of the ARF(1–22) peptide is associated with low membrane disturbance, measured by deoxyglucose and lactate dehydrogenase (LDH) leakage, as compared to its scrambled peptide. Also, flow cytometric analysis of annexin V/propidium iodide (PI) binding and Hoechst staining of nuclei suggest that ARF(1–22) induces apoptosis, whereas scrambled or inverted peptide sequences have no effect. The ARF(1–22) peptide mainly translocates cells through endocytosis, and is found intact inside cells for at least 3 hours. To our knowledge, this is the first time a CPP having pro-apoptopic activity has been designed from a protein.

1 August 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
EUEgon Urgard
Egon Urgard
ALAnnely Lorents
Annely Lorents
Mariliis KlaasMariliis Klaas
Mariliis Klaas
KPKärt Padari
Kärt Padari
JVJaneli Viil
Janeli Viil
ARAna Rebane
Ana Rebane

1 August 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SPSiim Pauklin
Siim Pauklin
AKArnold Kristjuhan
Arnold Kristjuhan
TMToivo Maimets
Toivo Maimets
VJViljar Jaks
Viljar Jaks

29 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAde Kallas
Ade Kallas
MPMartin Pook
Martin Pook
MMMartti Maimets
Martti Maimets
KZKülli Zimmermann
Külli Zimmermann
TMToivo Maimets
Toivo Maimets
Nocodazole is a known destabiliser of microtubule dynamics and arrests cell-cycle at the G2/M phase. In the context of the human embryonic stem cell (hESC) it is important to understand how this arrest influences the pluripotency of cells. Here we report for the first time the changes in the expression of transcription markers Nanog and Oct4 as well as SSEA-3 and SSEA-4 in human embryonic cells after their treatment with nocodazole. Multivariate permeabilised-cell flow cytometry was applied for characterising the expression of Nanog and Oct4 during different cell cycle phases. Among untreated hESC we detected Nanog-expressing cells, which also expressed Oct4, SSEA-3 and SSEA-4. We also found another population expressing SSEA-4, but without Nanog, Oct4 and SSEA-3 expression. Nocodazole treatment resulted in a decrease of cell population positive for all four markers Nanog, Oct4, SSEA-3, SSEA-4. Nocodazole-mediated cell-cycle arrest was accompanied by higher rate of apoptosis and upregulation of p53. Twenty-four hours after the release from nocodazole block, the cell cycle of hESC normalised, but no increase in the expression of transcription markers Nanog and Oct4 was detected. In addition, the presence of ROCK-2 inhibitor Y-27632 in the medium had no effect on increasing the expression of pluripotency markers Nanog and Oct4 or decreasing apoptosis or the level of p53. The expression of SSEA-3 and SSEA-4 increased in Nanog-positive cells after wash-out of nocodazole in the presence and in the absence of Y-27632. Our data show that in hESC nocodazole reversible blocks cell cycle, which is accompanied by irreversible loss of expression of pluripotency markers Nanog and Oct4.

1 June 1990
Verified
Journal Article
Closed access
HSH W Stürzbecher
H W Stürzbecher
TMToivo Maimets
Toivo Maimets
PCPeter Chumakov
Peter Chumakov
RBR Brain
R Brain
CAC Addison
C Addison
WCW Court
W Court